Cargando…
Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy
BACKGROUND: Clinical application of cancer immunotherapy requires a better understanding of tumor immunogenicity and the tumor microenvironment. HLA class I molecules present antigens to CD8(+) cytotoxic cells. Their loss or downregulation is frequently found in tumors resulting in reduced T cell re...
Autores principales: | Sinn, Bruno Valentin, Weber, Karsten E., Schmitt, Wolfgang Daniel, Fasching, Peter A., Symmans, William Fraser, Blohmer, Jens-Uwe, Karn, Thomas, Taube, Eliane Tabea, Klauschen, Frederick, Marmé, Frederik, Schem, Christian, Stickeler, Elmar, Ataseven, Beyhan, Huober, Jens, von Minckwitz, Gunter, Seliger, Barbara, Denkert, Carsten, Loibl, Sibylle |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6907189/ https://www.ncbi.nlm.nih.gov/pubmed/31829264 http://dx.doi.org/10.1186/s13058-019-1231-z |
Ejemplares similares
-
EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy
por: Leichsenring, Jonas, et al.
Publicado: (2022) -
Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial
por: Witzel, Isabell, et al.
Publicado: (2019) -
DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status
por: Jurmeister, Philipp, et al.
Publicado: (2021) -
Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC
por: Massa, Chiara, et al.
Publicado: (2020) -
MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial
por: Jank, Paul, et al.
Publicado: (2020)